Shiyi Sun, Lihong Chen, Dawei Chen, Yan Li, Guanjian Liu, Lin Ma, Jun Li, Fangwei Cao, Xingwu Ran
{"title":"中国糖尿病患者高尿酸血症患病率及相关因素:一项横断面研究","authors":"Shiyi Sun, Lihong Chen, Dawei Chen, Yan Li, Guanjian Liu, Lin Ma, Jun Li, Fangwei Cao, Xingwu Ran","doi":"10.1177/20420188231198620","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>As a part of metabolic syndrome, hyperuricemia has a higher incidence in patients with diabetes than in the general population owing to various underlying factors.</p><p><strong>Objectives: </strong>The objective of the present study was to investigate the prevalence of hyperuricemia among patients with diabetes and identify associated factors.</p><p><strong>Design: </strong>A cross-sectional study.</p><p><strong>Methods: </strong>Herein, we included patients with diabetes managed at nine healthcare centers in Chenghua District, Chengdu, from February 2021 to November 2021. Clinical data, lifestyle habits, and laboratory data were collected to determine the prevalence and factors associated with hyperuricemia.</p><p><strong>Results: </strong>In total, we included 1577 patients with diabetes (males, 50.35%; females, 49.65%). The median serum uric acid level was 337.9 μmol/L, and the prevalence of hyperuricemia in patients with diabetes was 21.24%. The prevalence of hyperuricemia in male patients was significantly higher than in females (29.35% in males <i>versus</i> 13.03% in females, <i>p</i> < 0.001). Male patients with obesity (<i>p</i> = 0.006) or triglyceride (TG) ⩾ 1.7 mmol/L (<i>p</i> < 0.001) had a high risk of developing hyperuricemia, and hyperuricemia was negatively associated with estimated glomerular filtration rate (eGFR) ⩾ 60 mL/min/1.73 m<sup>2</sup> (<i>p</i> < 0.001), glycosylated hemoglobin (HbA1c) ⩾ 7% (<i>p</i> < 0.001), fenofibrate (<i>p</i> = 0.010), and sodium-glucose cotransporter 2 (SGLT-2) inhibitors (<i>p</i> = 0.035). Considering females, overweight (<i>p</i> = 0.004), alanine transaminase (ALT) > 40 U/L (<i>p</i> < 0.001), and TG ⩾ 1.7 mmol/L (<i>p</i> = 0.015) showed a significant positive correlation with hyperuricemia, while eGFR ⩾ 60 mL/min/1.73 m<sup>2</sup> (<i>p</i> < 0.001) was negatively associated with the risk of hyperuricemia.</p><p><strong>Conclusion: </strong>Hyperuricemia is highly prevalent in patients with diabetes, especially in males. In addition to traditionally associated factors, fenofibrate and SGLT-2 inhibitors were also associated with the risk of hyperuricemia.</p><p><strong>Registration: </strong>The study protocol was registered in the Chinese Clinical Trial Registry (http://www.chictr.org.cn/), and the registration number was ChiCTR 2100042742.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/dc/10.1177_20420188231198620.PMC10501065.pdf","citationCount":"0","resultStr":"{\"title\":\"Prevalence and associated factors of hyperuricemia among Chinese patients with diabetes: a cross-sectional study.\",\"authors\":\"Shiyi Sun, Lihong Chen, Dawei Chen, Yan Li, Guanjian Liu, Lin Ma, Jun Li, Fangwei Cao, Xingwu Ran\",\"doi\":\"10.1177/20420188231198620\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>As a part of metabolic syndrome, hyperuricemia has a higher incidence in patients with diabetes than in the general population owing to various underlying factors.</p><p><strong>Objectives: </strong>The objective of the present study was to investigate the prevalence of hyperuricemia among patients with diabetes and identify associated factors.</p><p><strong>Design: </strong>A cross-sectional study.</p><p><strong>Methods: </strong>Herein, we included patients with diabetes managed at nine healthcare centers in Chenghua District, Chengdu, from February 2021 to November 2021. Clinical data, lifestyle habits, and laboratory data were collected to determine the prevalence and factors associated with hyperuricemia.</p><p><strong>Results: </strong>In total, we included 1577 patients with diabetes (males, 50.35%; females, 49.65%). The median serum uric acid level was 337.9 μmol/L, and the prevalence of hyperuricemia in patients with diabetes was 21.24%. The prevalence of hyperuricemia in male patients was significantly higher than in females (29.35% in males <i>versus</i> 13.03% in females, <i>p</i> < 0.001). Male patients with obesity (<i>p</i> = 0.006) or triglyceride (TG) ⩾ 1.7 mmol/L (<i>p</i> < 0.001) had a high risk of developing hyperuricemia, and hyperuricemia was negatively associated with estimated glomerular filtration rate (eGFR) ⩾ 60 mL/min/1.73 m<sup>2</sup> (<i>p</i> < 0.001), glycosylated hemoglobin (HbA1c) ⩾ 7% (<i>p</i> < 0.001), fenofibrate (<i>p</i> = 0.010), and sodium-glucose cotransporter 2 (SGLT-2) inhibitors (<i>p</i> = 0.035). Considering females, overweight (<i>p</i> = 0.004), alanine transaminase (ALT) > 40 U/L (<i>p</i> < 0.001), and TG ⩾ 1.7 mmol/L (<i>p</i> = 0.015) showed a significant positive correlation with hyperuricemia, while eGFR ⩾ 60 mL/min/1.73 m<sup>2</sup> (<i>p</i> < 0.001) was negatively associated with the risk of hyperuricemia.</p><p><strong>Conclusion: </strong>Hyperuricemia is highly prevalent in patients with diabetes, especially in males. In addition to traditionally associated factors, fenofibrate and SGLT-2 inhibitors were also associated with the risk of hyperuricemia.</p><p><strong>Registration: </strong>The study protocol was registered in the Chinese Clinical Trial Registry (http://www.chictr.org.cn/), and the registration number was ChiCTR 2100042742.</p>\",\"PeriodicalId\":22998,\"journal\":{\"name\":\"Therapeutic Advances in Endocrinology and Metabolism\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/dc/10.1177_20420188231198620.PMC10501065.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Endocrinology and Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20420188231198620\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Endocrinology and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420188231198620","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
背景:高尿酸血症作为代谢综合征的一部分，由于多种潜在因素的影响，糖尿病患者的发病率高于一般人群。目的:本研究的目的是调查糖尿病患者中高尿酸血症的患病率并确定相关因素。设计:横断面研究。方法:本研究纳入了2021年2月至2021年11月在成都市成华区9个医疗中心管理的糖尿病患者。收集临床资料、生活习惯和实验室数据，以确定高尿酸血症的患病率和相关因素。结果:共纳入糖尿病患者1577例(男性50.35%;女性,49.65%)。血清尿酸中位数为337.9 μmol/L，糖尿病患者高尿酸血症患病率为21.24%。男性患者的高尿酸血症患病率显著高于女性(男性29.35%，女性13.03%，p p = 0.006)或甘油三酯(TG)小于1.7 mmol/L (p 2 (p p = 0.010))，以及钠-葡萄糖共转运蛋白2 (SGLT-2)抑制剂(p = 0.035)。考虑到女性，超重(p = 0.004)，谷丙转氨酶(ALT) > 40 U/L (p p = 0.015)与高尿酸血症呈显著正相关，而eGFR大于或等于60 mL/min/1.73 m2 (p结论:高尿酸血症在糖尿病患者中非常普遍，尤其是在男性中。除了传统的相关因素外，非诺贝特和SGLT-2抑制剂也与高尿酸血症的风险相关。注册:研究方案在中国临床试验注册中心(http://www.chictr.org.cn/)注册，注册号为ChiCTR 2100042742。
Prevalence and associated factors of hyperuricemia among Chinese patients with diabetes: a cross-sectional study.
Background: As a part of metabolic syndrome, hyperuricemia has a higher incidence in patients with diabetes than in the general population owing to various underlying factors.
Objectives: The objective of the present study was to investigate the prevalence of hyperuricemia among patients with diabetes and identify associated factors.
Design: A cross-sectional study.
Methods: Herein, we included patients with diabetes managed at nine healthcare centers in Chenghua District, Chengdu, from February 2021 to November 2021. Clinical data, lifestyle habits, and laboratory data were collected to determine the prevalence and factors associated with hyperuricemia.
Results: In total, we included 1577 patients with diabetes (males, 50.35%; females, 49.65%). The median serum uric acid level was 337.9 μmol/L, and the prevalence of hyperuricemia in patients with diabetes was 21.24%. The prevalence of hyperuricemia in male patients was significantly higher than in females (29.35% in males versus 13.03% in females, p < 0.001). Male patients with obesity (p = 0.006) or triglyceride (TG) ⩾ 1.7 mmol/L (p < 0.001) had a high risk of developing hyperuricemia, and hyperuricemia was negatively associated with estimated glomerular filtration rate (eGFR) ⩾ 60 mL/min/1.73 m2 (p < 0.001), glycosylated hemoglobin (HbA1c) ⩾ 7% (p < 0.001), fenofibrate (p = 0.010), and sodium-glucose cotransporter 2 (SGLT-2) inhibitors (p = 0.035). Considering females, overweight (p = 0.004), alanine transaminase (ALT) > 40 U/L (p < 0.001), and TG ⩾ 1.7 mmol/L (p = 0.015) showed a significant positive correlation with hyperuricemia, while eGFR ⩾ 60 mL/min/1.73 m2 (p < 0.001) was negatively associated with the risk of hyperuricemia.
Conclusion: Hyperuricemia is highly prevalent in patients with diabetes, especially in males. In addition to traditionally associated factors, fenofibrate and SGLT-2 inhibitors were also associated with the risk of hyperuricemia.
Registration: The study protocol was registered in the Chinese Clinical Trial Registry (http://www.chictr.org.cn/), and the registration number was ChiCTR 2100042742.
期刊介绍：
Therapeutic Advances in Endocrinology and Metabolism delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of endocrinology and metabolism.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
